ClinicalTrials.gg

Program

cobimetinib

Also written as “Cobimetinib”, “HM95573, cobimetinib” and “GDC-0973 IV Infusion”.

Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Neoplasms · Ovarian Neoplasms, led by 2 companies.

Furthest: phase 3, since Sep 18, 201238 company-led studies, 6 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche364 open or runningphase 3since Sep 18, 2012Apr 18, 2007Nov 30, 2026phase 2 · NCT04302025
Hanmi Pharmaceutical22 open or runningphase 2since Feb 27, 2026Aug 7, 2017Sep 2029phase 2 · NCT07449754

Also a collaborator on its studies: Halozyme Therapeutics and biolinerx-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 24 studies since Apr 18, 2007.

  1. Jun 5, 2017Phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03178552 · 1,000 enrolled · United States, Argentina, Australia and more
  2. Jun 9, 2017Phase 2 study in Pancreatic AdenocarcinomaHoffmann-La Roche · NCT03193190 · 341 enrolled · United States, Germany, Japan and more
  3. Aug 7, 2017Hanmi Pharmaceutical's first study: phase 1 study in Neoplasm MetastasisNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT03284502 · 148 enrolled · Korea, Republic of
  4. Aug 17, 2017Phase 2 study in Solid TumorsHoffmann-La Roche · NCT03264066 · 87 enrolled · United States, Belgium, Germany and more
  5. Sep 1, 2017Phase 3 study in Advanced BRAFV600 Wild-type MelanomaHoffmann-La Roche · NCT03273153 · 446 enrolled · United States, Australia, Belgium and more
  6. Sep 11, 2017Phase 2 study in Esophageal NeoplasmsHoffmann-La Roche · NCT03281369 · 219 enrolled · United States, Australia, Israel and more
  7. Oct 12, 2017Phase 2 study in Multiple MyelomaHoffmann-La Roche · NCT03312530 · 49 enrolled · Czechia, Denmark, France and more
  8. Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03337698 · 314 enrolled · United States, Australia, France and more
  9. Aug 2, 2018Phase 2 study in MelanomaHoffmann-La Roche · NCT03625141 · 80 enrolled · Brazil, France, Germany and more
  10. Sep 30, 2018Phase 1 study in Ovarian NeoplasmsHoffmann-La Roche · NCT03695380 · 77 enrolled · United States, Italy, Spain
  11. Mar 6, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT04302025 · 99 enrolled · United States
  12. Apr 6, 2021Phase 1 study in MelanomaHoffmann-La Roche · NCT04835805 · 65 enrolled · United States, Australia, Canada and more
  13. Jun 9, 2021Phase 2 study in Ovarian NeoplasmsHoffmann-La Roche · NCT04931342 · 176 enrolled · United States, Australia, Canada and more
  14. Feb 27, 2026Phase 2 study in MelanomaPhase 2 reachedHanmi Pharmaceutical · NCT07449754 · 45 planned · South Korea

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT04302025
  2. Dec 31, 2026Primary completion: phase 1 study in MelanomaHoffmann-La Roche · NCT04835805
  3. Jun 30, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03178552
  4. Feb 28, 2028Primary completion: phase 2 study in Ovarian NeoplasmsHoffmann-La Roche · NCT04931342

TargetBeta

“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
pimasertibruleMerck KGaA, Darmstadt, Germanyphase 213
mirdametinibruleMerck KGaA, Darmstadt, Germanyphase 29
polfurmetinibPfizerphase 13

Studies

All 38 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07449754Melanoma · South Korea2RecruitingHanmi PharmaceuticalSep 202945
NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more2Active, not recruitingHoffmann-La RocheFeb 28, 2028176
NCT04835805Melanoma · United States, Australia, Canada and more1Active, not recruitingHoffmann-La RocheDec 31, 202665
NCT04302025Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingHoffmann-La RocheNov 30, 202699
NCT03695380Ovarian Neoplasms · United States, Italy, Spain1CompletedHoffmann-La RocheJul 12, 202377
NCT03625141Melanoma · Brazil, France, Germany and more2CompletedHoffmann-La RocheJun 7, 202180
NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more2TerminatedHoffmann-La RocheOct 14, 2025314
NCT03312530Multiple Myeloma · Czechia, Denmark, France and more2CompletedHoffmann-La RocheMay 18, 202149
NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more2TerminatedHoffmann-La RocheOct 9, 2025219
NCT03273153Advanced BRAFV600 Wild-type Melanoma · United States, Australia, Belgium and more3TerminatedHoffmann-La RocheApr 15, 2019446
NCT03264066Solid Tumors · United States, Belgium, Germany and more2CompletedHoffmann-La RocheJun 25, 202087
NCT03284502Neoplasm Metastasis · Korea, Republic of1Active, not recruitingHanmi PharmaceuticalSep 30, 2024148
NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more2CompletedHoffmann-La RocheFeb 27, 2025341
NCT03178552Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingHoffmann-La RocheJun 30, 20271,000
NCT03178851Melanoma · United States, Australia, Bosnia and Herzegovina and more1CompletedHoffmann-La RocheMay 29, 2019155
NCT02876224Colorectal Neoplasms · United States, Spain1CompletedHoffmann-La RocheJun 25, 201951
NCT02788279Colorectal Neoplasms · United States, Australia, Belgium and more3CompletedHoffmann-La RocheMar 9, 2018363
NCT02670044Leukemia, Myeloid, Acute · United States, Canada, France and more1CompletedHoffmann-La RocheDec 10, 202088
NCT02639546Solid Tumors · United States, France, Germany and more2CompletedHoffmann-La RocheJul 21, 202156
NCT02457793Carcinoma, Non-Small-Cell Lung · United States1CompletedHoffmann-La RocheDec 5, 201624
NCT02322814Breast Neoplasms · United States, Australia, Belgium and more2TerminatedHoffmann-La RocheAug 10, 2018169
NCT02300025Healthy Volunteer · United States1CompletedHoffmann-La RocheJan 201528
NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more2CompletedHoffmann-La RocheMay 31, 20191,044
NCT02136524Healthy Volunteer · United States1CompletedHoffmann-La RocheMay 201428
NCT02091141Neoplasms · United States2CompletedHoffmann-La RocheMay 24, 2023673
NCT01988896Solid Tumors · United States, Australia, Canada and more1CompletedHoffmann-La RocheNov 4, 2019153
NCT01986166Neoplasms · United States, Spain1CompletedHoffmann-La RocheJan 201623
NCT01974258Neoplasms · United States1WithdrawnHoffmann-La RocheJul 20140
NCT01929876Healthy Participants · United States1CompletedHoffmann-La RocheOct 201316
NCT01711762Healthy Volunteer · United States1CompletedHoffmann-La RocheSep 20126
NCT01689519Melanoma · United States, Australia, Austria and more3CompletedHoffmann-La RocheMay 9, 2014495
NCT01562275Neoplasms · United States, Spain1CompletedHoffmann-La RocheJan 201567
NCT01277718Healthy Volunteer1CompletedHoffmann-La RocheFeb 201120
NCT01271803Melanoma · United States, Australia1CompletedHoffmann-La RocheOct 1, 2013131
NCT01249131Healthy Volunteers1CompletedHoffmann-La RocheJan 10, 201120
NCT01249118Healthy Volunteers1CompletedHoffmann-La RocheJan 201113
NCT00996892Hereditary Sensory and Autonomic Neuropathies · United States1TerminatedHoffmann-La RocheMar 2014178
NCT00467779Solid Tumor · United States1CompletedHoffmann-La RocheApr 2014119

How it is read

Names in the registry

  • “Cobimetinib”, 34 entries
  • “cobimetinib”, 4 entries
  • “HM95573, cobimetinib”, 2 entries
  • “GDC-0973 IV Infusion”, 1 entry
  • “GDC-0973 Oral Capsules”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.